Anders Lundin

Anders Lundin is the current CFO at Q-linea. Prior to their current position, they held various interim positions including Interim CFO, IR & Com at Medivir AB, Interim Financial Consultant and Production Business Control at Sandvik Coromant, and Interim CFO at Oasmia Pharmaceutical AB and BioPhausia AB.

At Medivir AB, Anders was responsible for filling the position of CFO until a permanent replacement could be found. Anders also prepared and executed a directed issue of SEK 155 million, which required cooperation and communication with banks, lawyers, and other stakeholders. In addition, they oversaw the IR function and was primarily responsible for insider reporting.

At Sandvik Coromant, Anders served as an interim financial consultant and production business control. In this role, they were responsible for production controlling and process enhancements.

At Oasmia Pharmaceutical AB, Anders served as Interim CFO. Anders was responsible for secure post-IPO reporting requirements to SEC (Security and Exchange Commission), which included POS AM : Post-effective amendment to a F-1 registration statement and a 20-F Annual report. Anders also drove an internal control project to comply with SOX 302 and prepare for SOX 404. Furthermore, they reported to Swedish market reports of 2015/2016 Year End report and Annual reports and Q1 Interim report.

Lastly, at BioPhausia AB, Anders also served as Interim CFO.

Their manager is Jonas Jarvius, CEO. They work with Thomas Fritz - Chief Commercial Officer , Nils Kristensen - COO, and Jonas Melin - Director Product Development.